Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected Melanoma.
Sign Up to like & getrecommendations! Published in 2021 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2021.0051
Abstract: Importance Agents targeting programmed cell death 1 (PD-1)/PD ligand 1 (PD-L1) improve long-term survival across many advanced cancers and are now used as adjuvant therapy for resected stage III and IV melanomas. The incidence and… read more here.
Keywords: chronic immune; anti therapy; immune related; therapy ... See more keywords
Insights on chronic immune thrombocytopenia pathogenesis: A bench to bedside update.
Sign Up to like & getrecommendations! Published in 2021 at "Blood reviews"
DOI: 10.1016/j.blre.2021.100827
Abstract: Immune thrombocytopenia (ITP) is a heterogeneous disease with an unpredictable course. Chronicity can develop in up to two-thirds of adults and 20-25% of children, representing a significant burden on patients' quality of life. Despite acceptable… read more here.
Keywords: chronic immune; thrombocytopenia; insights chronic; thrombocytopenia pathogenesis ... See more keywords
Changes in DNA Methylation of Glucocorticoid-Induced Tumor Necrosis Factor Receptor and Its Ligand in Liver Transplantation.
Sign Up to like & getrecommendations! Published in 2017 at "Transplantation proceedings"
DOI: 10.1016/j.transproceed.2017.06.023
Abstract: Liver transplantation (LT) is the criterion standard of care in patients with end-stage liver disease and those with tumors of hepatic origin in the setting of liver dysfunction. Chronic immune rejection of the liver transplant… read more here.
Keywords: chronic immune; methylation; liver; liver transplantation ... See more keywords
SARS-CoV-2 in severe COVID-19 induces a TGF-β-dominated chronic immune response that does not target itself
Sign Up to like & getrecommendations! Published in 2021 at "Nature Communications"
DOI: 10.1038/s41467-021-22210-3
Abstract: The pathogenesis of severe COVID-19 reflects an inefficient immune reaction to SARS-CoV-2. Here we analyze, at the single cell level, plasmablasts egressed into the blood to study the dynamics of adaptive immune response in COVID-19… read more here.
Keywords: chronic immune; covid; immune response; sars cov ... See more keywords
Rationally designed bacterial consortia to treat chronic immune-mediated colitis and restore intestinal homeostasis
Sign Up to like & getrecommendations! Published in 2021 at "Nature Communications"
DOI: 10.1038/s41467-021-23460-x
Abstract: Environmental factors, mucosal permeability and defective immunoregulation drive overactive immunity to a subset of resident intestinal bacteria that mediate multiple inflammatory conditions. GUT-103 and GUT-108, live biotherapeutic products rationally designed to complement missing or underrepresented… read more here.
Keywords: mediated colitis; chronic immune; colitis; immune mediated ... See more keywords
Chronic immune thrombocytopenia in a child with X-linked agammaglobulinemia-an uncommon phenotype
Sign Up to like & getrecommendations! Published in 2022 at "Platelets"
DOI: 10.1080/09537104.2022.2053090
Abstract: Abstract Autoimmune disorders are common in patients with primary immunodeficiency diseases (PIDs). However, the prevalence of autoimmunity is low in patients with X-linked agammaglobulinemia (XLA), mostly due to the absence of antibodies. Chronic or persistent… read more here.
Keywords: immune thrombocytopenia; phenotype; chronic immune; thrombocytopenia child ... See more keywords
An updated evaluation of avatrombopag for the treatment of chronic immune thrombocytopenia
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Clinical Immunology"
DOI: 10.1080/1744666x.2022.2098119
Abstract: ABSTRACT Introduction Multiple agents are available for the management of chronic immune thrombocytopenia (ITP), including thrombopoietin-receptor agonists (TPO-RAs), rituximab, and fostamatinib. Although TPO-RAs are often selected as treatments for chronic ITP, when choosing between the… read more here.
Keywords: chronic immune; immune thrombocytopenia; tpo ras; avatrombopag ... See more keywords
Reversible Conduction Failure in Chronic Immune-Mediated Sensorimotor and Autonomic Polyneuropathy.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Neuromuscular Disease"
DOI: 10.1097/cnd.0000000000000232
Abstract: Reversible conduction failure (RCF) has been described in several subtypes of Guillain-Barre syndrome and is typically observed within the first 10 weeks. We describe the presence of RCF lasting for at least 9 months or… read more here.
Keywords: sensorimotor autonomic; conduction; reversible conduction; chronic immune ... See more keywords
Cutaneous Hemorrhage Types as Supportive Factors for Predicting Chronic Immune Thrombocytopenia in Children
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Pediatric Hematology/Oncology"
DOI: 10.1097/mph.0000000000001167
Abstract: Our objective was to assess risk factors for developing chronic immune thrombocytopenia (ITP) in children. The charts of all consecutive children diagnosed with ITP between 2000 and 2015 at a single center were retrospectively reviewed,… read more here.
Keywords: hemorrhage types; chronic immune; risk; immune thrombocytopenia ... See more keywords
An alternative intermittent eltrombopag dosing protocol for the treatment of chronic immune thrombocytopenia
Sign Up to like & getrecommendations! Published in 2018 at "British Journal of Clinical Pharmacology"
DOI: 10.1111/bcp.13717
Abstract: Eltrombopag, an oral thrombopoietin receptor agonist, is dosed daily to treat chronic immune thrombocytopenia (ITP). As it has a half-life of 26-35 h in ITP patients and requires patents to abide by strict dietary restrictions that… read more here.
Keywords: alternative intermittent; chronic immune; intermittent eltrombopag; treatment ... See more keywords
Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia
Sign Up to like & getrecommendations! Published in 2018 at "British Journal of Haematology"
DOI: 10.1111/bjh.15573
Abstract: Avatrombopag, an oral thrombopoietin receptor agonist, was compared with placebo in a 6‐month, multicentre, randomised, double‐blind, parallel‐group Phase 3 study, with an open‐label extension phase, to assess the efficacy and safety of avatrombopag (20 mg/day)… read more here.
Keywords: phase; chronic immune; receptor agonist; immune thrombocytopenia ... See more keywords